Welcome to our dedicated page for Ionq SEC filings (Ticker: IONQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IonQ, Inc. (NYSE: IONQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a quantum platform company active in computing, networking, sensing, and security, IonQ uses its SEC filings to report on capital markets activity, acquisitions, governance changes, and executive compensation arrangements.
Investors can review Form 8-K filings where IonQ reports material events such as underwriting agreements for common stock, pre-funded warrants, and Series B warrants, as well as prospectus supplements covering resales of common stock by selling stockholders. Other 8-Ks describe unregistered sales of equity securities, registration rights agreements with institutions like Oxford Science Enterprises and Fortis Advisors, and the completion of acquisitions such as Oxford Ionics Limited and Vector Atomic, Inc.
Filings also detail board and executive changes. Recent 8-Ks and amendments outline the appointment of new directors, the transition of existing directors into advisory roles, and separation agreements for senior executives under IonQ’s Amended and Restated Executive Severance Plan. These documents specify cash severance, COBRA benefits, and equity vesting terms, providing insight into leadership transitions and compensation structures.
Through its registration statements and related supplements, IonQ discloses information about listed securities, including common stock and warrants trading on the New York Stock Exchange under the symbols IONQ and IONQ WS. AI-generated highlights on this page help users quickly identify key terms such as warrant exercise prices, expiration dates, and adjustment mechanisms, as well as the implications of registration rights and resale arrangements.
By using this filings page, readers can follow IonQ’s equity offerings, acquisition-related share issuances, insider and governance updates, and other regulatory disclosures, while AI summaries assist in understanding how each filing may relate to ownership, dilution, and the company’s strategic transactions.
Insider reported RSU awards and resulting beneficial ownership in IonQ, Inc. (IONQ). Robert T. Cardillo received two restricted stock unit awards on 09/10/2025: 45,600 RSUs that vest over four years (25% on 09/10/2026, then quarterly 1/16 on each Dec 10, Mar 10, Jun 10, Sep 10) and 31,920 RSUs that vest in full on 09/10/2027, both conditioned on continued service. Both awards were reported with a transaction price of $0. After the first award the reporting person beneficially owned 83,036 shares, and after the second award 114,956 shares. The filing was signed by an attorney-in-fact on 09/25/2025.
IonQ amended a prior 8-K to correct a typographical error and to confirm transaction terms. The amendment states the company delivered 25,372,150 shares of common stock plus $10,000,000 cash as the aggregate consideration at closing for the acquisition of Oxford Ionics Limited. The amendment corrects an earlier, incorrect share amount of 26,622,077. It also discloses a proposed issuance of 6,294,058 shares in connection with the Vector Atomic transaction, expected to close in the fourth quarter of 2025 and subject to customary conditions. The filing references a registration rights agreement and related press releases and confirms reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ director Robert T. Cardillo exercised and sold company stock under a Rule 10b5-1 plan. On 09/12/2025 the reporting person exercised a stock option with an $11.24 exercise price to acquire 8,773 shares and immediately sold 8,773 shares at a weighted-average price of $50.5177, with individual sale prices ranging from $47.38 to $55.65.
Following these transactions the reporting person beneficially owned 37,436 shares. The Form 4 states the trades were executed pursuant to a 10b5-1 trading plan adopted March 12, 2025 and amended June 13, 2025, and discloses vesting terms for the option: one-third vested on February 26, 2025 with annual vesting thereafter.
IonQ director and Chief Administrative Officer Paul T. Dacier sold 4,175 shares of IonQ common stock on 09/11/2025 at a weighted average price of $44.4016 per share, reducing his beneficial ownership to 114,454 shares. The filing states the sale was a "sell-to-cover" to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units, and the reported sales occurred at prices ranging from $43.41 to $45.505. The Form 4 was signed by an attorney-in-fact on 09/12/2025.
IonQ insider sale related to tax withholding on vested RSUs. Chief Revenue Officer Rima Alameddine sold 19,976 shares of IonQ common stock on 09/11/2025 as a "sell-to-cover" to satisfy statutory tax withholding following RSU vesting. The weighted average price reported for the shares sold was $44.4016, with individual sale prices ranging from $43.41 to $45.505. After the transactions, the reporting person beneficially owned 532,616 shares, reported as direct ownership. The filing was signed by an attorney-in-fact on 09/12/2025. Explanatory footnotes state the sale was mandated by the issuer's equity plan and not a discretionary sale by the reporting person.
IonQ, Inc. director and President & CEO Niccolo de Masi reported the sale of 16,120 shares of IonQ common stock on 09/11/2025. The filing states these sales were executed as a sell-to-cover to satisfy statutory tax withholding obligations upon vesting of restricted stock units, not as discretionary open-market dispositions. The weighted-average price for the shares sold is reported as $44.4016, with individual trade prices ranging from $43.41 to $45.505. After the transaction, de Masi beneficially owns 1,181,186 shares, held directly.
IonQ, Inc. insider filing reports a proposed sale of 129,670 common shares through Morgan Stanley on 09/12/2025, with an aggregate market value of $6,100,973.50. The shares were originally acquired on 02/24/2021 from the issuer by exercise of stock options, paid in cash. The filing lists total outstanding shares of 296,837,796, and discloses that the same account sold 461,214 shares under 10b5-1 plans during the prior three months, generating gross proceeds of $19,044,783.58. The filer certifies there is no undisclosed material adverse information and references Rule 10b5-1 plan usage.
IonQ Form 144 filing summary
The filing notifies a proposed sale of 8,773 shares of IonQ common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $412,769.65. The shares represent a portion of the issuer's reported 296,837,796 outstanding shares. The filer acquired the shares on 09/12/2025 by exercising stock options and paid cash on the same date. The filer reports no securities sold in the past three months for the account. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Ionq (IONQ)?
What is the market cap of Ionq (IONQ)?
